GSK3B and colorectal carcinoma: Immunoblot experiments showed that treatment of CRC cells with ralimetinib (Additional file 1: Fig. S1A) or a specific siRNA (Additional file 1: Fig. S1B) decreases the phosphorylation inhibitory signal of GSK3β while increasing the phospho-degradation signal of β-catenin (p-β-catenin S33/37/T41).